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Abstract
MicroRNAs (miRNAs) are small noncoding RNAs with regulatory
functions, which play an important role in breast cancer. Several
studies have shown that miRNAs can act either as tumor
suppressors or as oncogenes, and that measurement of miRNA
expression in malignancies may have diagnostic and prognostic
implications. This article highlights a series of three recent studies
that prove the involvement of miRNAs in breast cancer metastases.
The first proves that miR-10b indirectly activates the pro-metastatic
gene  RHOC by suppressing HOXD10, thus leading to tumor
invasion and metastasis. The second proves that miR-373 and miR-
520c can also promote tumor invasion and metastasis, at least in
part by regulating the gene CD44. The third identifies miR-335, miR-
206, and miR-126 as suppressors of breast cancer metastasis. Loss
of miR-335 leads to the activation of SOX4 and TNC (encoding
tenascin C), which are responsible for the acquisition of metastatic
properties. Altogether, these remarkable findings are important for
our understanding of malignant transformation in the breast and may
have implications for the management of patients with advanced
breast cancer. The use of miRNAs as anticancer therapeutic agents
is promising, and such fine molecular studies certainly help in
bringing miRNAs closer to clinical practice.
miRNAs as cancer players: a balance
between repression of miRNA targets and
regulation of miRNA expression
MicroRNAs (miRNAs), which are short (19 to 24 nucleotides)
noncoding genes that are excised from 60- to 110-nucleotide
hairpin RNA precursors involved in the regulation of
expression of protein-coding genes (PCGs), became a focal
point in the molecular dissection of human cancer just a few
few years ago [1]. They represent a new class of gene
products whose functions are generally unknown. miRNA
binds to target mRNA by imperfect complementarity, causing
either mRNA degradation or translation inhibition. Recently, a
deviation from the above perspective on miRNA function was
identified;  miR-369-3 can upregulate translation of tumor
necrosis factor-α [2], which suggests an additional level of
complexity in miRNA function.
A growing list of reports demonstrate that miRNAs play a
critical role in cancer initiation and progression, and that
miRNA alterations are ubiquitous among human cancers.
Consequently, events that activate or inactivate miRNAs were
regarded to cooperate with PCG abnormalities in human
tumorigenesis [3]. For example, it was found that miRNAs
contribute to oncogenesis by functioning as downregulated
tumor suppressors, as is the case for the let-7 family, which
target RAS oncogenes in lung cancers, and miR-15a and miR-
16-1, which target the BCL2 oncogene in chronic lymphocytic
leukemias. It was also found that miRNAs can function as over-
expressed oncogenes, as is the case for the miR17-92 cluster,
which targetes the E2F1 oncogene in lymphomas, or miR-21,
which regulates the PTEN tumor suppressor in hepatocellular
carcinomas [4]. Much less was known about the upstream
regulation of miRNA in cancer cells until recently, when a series
of concomitant publications showed that the TP53 tumor
suppressor regulates transcription of the miR-34 family (for
review [5]) and mediate induction of apoptosis, cell cycle
arrest, and senescence by TP53. Furthermore, it was shown
that widespread miRNA repression by Myc contributes to
tumorigenesis [6] in general and to repression of the
oncogenic miR17-92 cluster [7] in particular.
Breast cancer metastasis: a balance between
suppression and activation by miRNAs
Involvement of miRNA in tumor initiation and progression has
come under intense scrutiny in recent years. The involvement
of miRNAs in the development of metastases was initially
discovered by Ma and coworkers [8] from Robert Weinberg’s
group who found that miR-10b initiates breast cancer
invasion and metastasis. Shortly afterward, Tavazzoie and
colleagues [9] of the Joan Massague group revealed that
miR-335 suppresses metastasis and migration by targeting
the transcription factor SOX4 and tenascin C, an extracellular
matrix component. At the same time, Huang and coworkers
[10] including the Reuven Agami group reported that miR-
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373 and  miR-520c stimulate cancer cell migration and
invasion, and proposed suppression of CD44 (which encodes
a cell surface receptor for hyaluronan) to be the underlying
mechanism. Taken together, these landmark studies reveal a
fine balance of noncoding RNAs as stimulators and inhibitors
of metastasis, and identify several targets that could potentially
represent the molecular link between miRNA deregulation and
a specific tumor behavior (Figure 1).
These are remarkable discoveries, not only because they
open a new field of investigation but also because the
authors finely dissected molecular pathways that are involved
in breast tumor metastasis (Figure 1). The study by Ma and
coworkers [8] revealed that upregulation of miR-10b
promotes invasion and metastasis. Whereas miR-10b is
downregulated in most breast cancers in comparison with
normal breast tissue [11], this miRNA is over-expressed in
about 50% of metastatic breast cancers [8]. The authors
proved that ectopic expression of miR-10b had no effect on
proliferation, but an increase in transwell migration and
Matrigel invasion was acquired by cells of two different
human breast cell lines. In vivo ectopic expression of
miR-10b conferred invasive properties on otherwise non-
invasive breast cancer cells; although control tumors could
not invade surrounding tissues and exhibited poor
vascularization, miR-10b over-expressing tumors exhibited an
invasive behavior and were highly vascularized. Moreover,
although lung micrometastases were detectable in miR-10b
over-expressing cells, no intravasating cells or lung meta-
stases were found in control tumors. Together, these findings
indicate that miR-10b can promote metastasis in otherwise
nonmetastatic breast cancer cells.
Then, Ma and coworkers [8] undertook the difficult task of
dissecting the molecular pathway linking miR-10b to the
metastatic process. First, they found that Twist, a metastasis-
promoting transcription factor, could induce miR-10b
expression and demonstrated that miR-10b is an essential
element in the Twist-induced metastasis program. Second,
they proved that HOXD10, a homeobox transcription factor
that promotes or maintains a differentiated phenotype in
epithelial cells, is a target of miR-10b. HOXD10 is indeed
expressed at low level in metastatic tumors. The authors
demonstrated the importance of HOXD10 as an effector of
miR-10b by showing that ectopic expression of HOXD10
that was unresponsive to miR-10b could abrogate miR-10b
induced cell motility and invasiveness. Finally, the authors
showed that RhoC, a G-protein involved in metastasis that is
repressed by HOXD10, becomes strongly expressed in
response to miR-10b expression. Importantly, reduction in
RhoC expression by small interfering RNA caused repression
of miR-10b induced cell migration and invasion, implying that
RhoC is a downstream effector of miR-10b [8].
The work by Huang and coworkers [10] revealed that
miR-373 and miR-520c are also metastasis-promoting micro-
RNAs. miR-373 was previously found to be associated with
testicular cancer but not with metastasis. Similarly to
miR-10b,  miR-373 and  miR-520c did not affect cell
proliferation, but promoted a migratory and invasive
phenotype of MCF7 cells in vitro. Furthermore, MCF7 cells
over-expressing miR-373 or miR-520c developed metastatic
nodules, which were instead absent in control cells.
Elucidating the molecular pathways involved, the authors
found that miR-373 and miR-520c ‘seed’ sequences were
similar, suggesting that they could regulate an overlapping
set of gene targets. Among nine shared potential gene
targets,  CD44 (which encodes a cell surface receptor for
hyaluronan) was found to be a direct target of both miR-373
and  miR-520c. Most importantly, ectopic expression of an
CD44 gene that was unresponsive to miR-373/miR-520c
could reduce the migratory properties of MCF7 cells over-
expressing miR-373/miR-520c. To verify the significance of
these results in primary breast carcinomas, the authors
analyzed 11 matched normal/tumor breast samples. They
found that miR-373 was upregulated in cancer, in particular
in tumors exhibiting lymph node metastasis. Moreover, an
inverse correlation with CD44 expression was identified.
These findings strengthen the significance of the studies
performed in breast cancer cell lines.
In contrast to the other studies, the team led by Joan
Massagué [9] found that miR-335, miR-126, and miR-206
are metastasis-suppressor miRNAs. To identify these miRNAs,
they compared miRNA expression of the metastatic nodules
versus the unselected breast cancer parental cells. These
Figure 1
microRNAs and PCGs: involvement in early (initiation), intermediate
(progression) and late (metastasis) steps in tumorigenesis. Presented
are the specific instances in which let-7 and miR-16 families (already
found to be involved in early stages of tumorigenesis), and miR-21 and
miR-221 proved to be involved in tumor progression. Also shown is
the newly described balance between miR-10b, miR-373, miR-520c,
and miR-335 in metastasis. The significant confirmed targets are also
shown. miRNA, microRNA; PGC, protein-coding gene.Page 3 of 4
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miRNAs were consistently downregulated in metastatic foci.
Moreover, the authors found that restoring the expression of
miR-335, miR-126, and miR-106 significantly decreased the
number of metastatic foci. To verify the relevance of these
findings in clinical samples, Massaguè and colleagues
analyzed the expression of these miRNAs in primary tumors.
They found that low expression of miR-335 or miR-126 was
significantly associated with poor metastasis-free survival.
Thus, these two miRNAs were markers for the likelihood of
developing metastasis. To elucidate the molecular basis of
these findings, the authors profiled metastatic cells with
restored miR-335 expression. Six PGCs were suppressed by
miR-335. Among these, knockdown of the transcription
factor SOX4 and TNC (encoding tenascin C) diminished in
vitro invasive ability and in vivo metastatic potential, indicating
that these genes are critical effectors of metastasis, which
are activated by loss of miR-335. Importantly, in an analysis of
published datasets on breast tumor gene expression, the
authors found that the expression of the six signature genes
was significantly associated with a poor metastasis-free
survival in a cohort of 368 patients. These findings suggest
the potential use of miR-335, its six PCG signature, and miR-
126 in prognostic stratification of breast cancer patients.
The consequences for scientists and patients:
a miRevolution in breast cancer
As with all breakthrough reports, these studies - published
over 4 months - have significant consequences. First, they
demonstrate that combination genome-wide profiling
followed by functional studies that involve over-expression
and downregulation of miRNAs represent the approach that
is most likely to yield advances in the field of noncoding RNA
research. Abnormal expression of tumor miRNAs, charac-
terized by differential levels of expression for mature and/or
precursor miRNA sequences as compared with normal cells,
has been proved to be the main abnormality, or ‘miRNoma’, in
cancer cells. Ma and colleagues [8] found that although miR-
10b was expressed at low levels in samples from metastasis-
free patients, this miRNA was overexpressed in about half of
the metastasis positive patients, a result that reconciles the
data with a previous published study in which miR-10b was
found downregulated in primary breast tumours [11]. Thus,
miR-10b was specifically over-expressed only in metastatic
cells, offering a rationale to investigate this miRNA. Further-
more, Tavazoie and colleagues [9] found that expression of
miR-335 (and miR-126) is lost in samples from patients with
relapsed breast cancer and that this loss of expression is
associated with poor distal metastases-free survival. Similarly,
Huang and colleagues [10] identified significant upregulation
of miR-373 in samples from patients with metastatic breast
cancer. Functional and molecular studies were essential for
elucidating the significance of the abnormal expression of this
miRNA in breast tumorigenesis.
A second implication of the three studies is that both the
main targets and the regulators of miRNA must be identified if
our understanding of the role played by miRNAs in complex
multistep processes (such as primary tumor invasion and
metastasis) is to improve. In the specific case of miR-10b,
this usually difficult process was rendered possible by the
extended experience of the Whitehead Institute group in
unraveling genetic programs that drive tumor metastasis.
Weinberg’s laboratory was involved in elucidating the Twist
signaling pathway during normal development and the
epithelial-mesenchymal transition program, and the
implications of this pathway for tumor metastasis (for review
[12]). The Twist/miR-10b/HOXD10/RHOC interrelation is
certainly a first example of metastasis-related interplay
between noncoding RNAs and cancer PCGs. In this regard,
a recent study showed that miR-21 (a ubiquitously over-
expressed miRNA in human cancers [13]) regulates cell
migration and invasion in hepatocellular cancer [4].
Massague’s group has a long track record of seminal
discoveries related to the molecular basis of metastasis (for
review [14]), whereas Agami’s group has much experience in
genetic screening with miRNA expression libraries, and
previous elegant work by the latter [15] identified miR-373 as
an oncogene in testicular germ cells tumors through direct
inhibition of the expression of the tumor suppressor LATS2.
The data reported by that group clearly demonstrate that the
same miRNA could target distinct PCGs in different types of
tumors and work in distinct signaling pathways.
Last but not at least, this recent work could have therapeutic
implications for the future. Most deaths from cancer are
associated with development of metastases, and prevention or
elimination of disseminated disease would have a major impact
on cancer mortality. The rationale for using miRNAs as potential
therapeutic targets is underpinned by the fact that miRNA over-
expression in cancer cells has a pathogenic effect [16].
Therefore, future phase I trials might demonstrate reduction in
miR-10b,  miR-373, and miR-520c levels in patients with
advanced breast cancer by various agents such as antisense
oligonucleotides against miRNAs, looked nucleic acids, anti-
miRNAs, or the antagomirs. On the other hand, over-expression
of miR-335 by mimic miRNAs could be another option to be
tested in patients. Although exciting, the use of miRNA-based
gene therapy in metastatic human cancers must still
demonstrate high efficiency of target inhibition, with
significantly improved patient survival and minimal toxicity.
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